These days’ nanotechnology‐based medicines, the nanomedicines (NMs) have gained attention as an effective treatment strategy to counter health issues like arthritis. Pre‐clinical research scientists, as well as physicians from all over the globe, support this approach. Therefore, Lu Liu and colleagues found out the targeted stimuli‐responsive NMs as a rheumatoid arthritis (RA) treatment approach in the last five years. Various milestones have been achieved in the clinical treatment of RA, but these therapies present certain shortcomings which begin from the adaptive treatment tolerance (ATT) following the long‐term drug use which leads to reduced efficacy, increasing sustained drug dose and critical adverse events. There is a need to establish innovative therapeutic approaches to overcome these challenges.

The nanotechnology‐based nanomedicines (NMs) are emerging as treatment for RA. One of the fundamental concepts in building more convenient multifunctional NMs formulations for efficient RA treatment is its targeted stimuli‐responsive features. Because of NMs delivery and on‐demand liberation of medicaments at targets in response to internal or external stimuli associated with the RA pathophysiology helps to postpone the RA progression efficiently and with no side effects on healthy tissues.